General Information of Drug (ID: DM2VQN5)

Drug Name
VALIOLAMINE Drug Info
Synonyms
Valiolamine; 83465-22-9; Valinolamine; (1S,2S,3R,4S,5S)-5-Amino-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol; Valiolamine hydrate; (1S,2S,3R,4S,5S)-5-amino-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; CHEMBL222396; AK109366; 4-Amino-3,4-dideoxy-2-C-(hydroxymethyl)-D-epi-inositol hydrate; C7H15NO5; BDBM50241137; D-epi-Inositol, 4-amino-3,4-dideoxy-2-C-(hydroxymethyl)-, hydrate; AC1L5B2J; CHEMBL9216; VDLOJRUTNRJDJO-ZYNSJIGGSA-N; MolPort-005-935-511; ZINC5157081; FCH856530; BDBM50024129; AKOS006287538; API0004565; AC-1555
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
174312
CAS Number
CAS 83465-22-9
TTD Drug ID
DM2VQN5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Avalglucosidase alfa DMPW5UF Pompe disease 5C51.3 Approved [2]
Deoxynojirimycin DM2ATZB Pompe disease 5C51.3 Phase 3 [1]
BMN-701 DM94Y6O Pompe disease 5C51.3 Phase 3 [3]
AT845 DMZJIIB Pompe disease 5C51.3 Phase 2 [4]
SALACINOL DMVKQT8 N. A. N. A. Phase 1/2 [5]
SPK-3006 DMK9DG5 Pompe disease 5C51.3 Phase 1/2 [6]
GZ402666 DMGO6M1 Pompe disease 5C51.3 Phase 1 [7]
5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one DMAJWLD Pompe disease 5C51.3 Preclinical [8]
Alpha-Homonojirimycin DMT17H0 Discovery agent N.A. Investigative [1]
7-O-b-D-Glucopyranosyl-a-homonojirimycin DM8IY3D Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysosomal alpha-glucosidase (GAA) TTLPC70 LYAG_HUMAN Inhibitor [1]

References

1 In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
2 ClinicalTrials.gov (NCT02782741) Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of BioMarin Pharma.
4 Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity. EMBO Mol Med. 2022 Jan 11;14(1):e13968.
5 Alpha-glucosidase inhibitor from Kothala-himbutu (Salacia reticulata WIGHT). J Nat Prod. 2008 Jun;71(6):981-4.
6 Clinical pipeline report, company report or official report of Spark Therapeutics
7 ClinicalTrials.gov (NCT01898364) Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.. U.S. National Institutes of Health.
8 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one Analogs as Inhibitors of Acid alpha-Glucosidase for Potential Chaperone Treatment of Pompe Disease or Intervention for Diabetes Mellitus Type 2. N.A.. N.A.